Identify potential candidates for additional therapy.
SmartKidney Dx™, in the final stage of development, is a biomarker- and algorithm-based direct tissue measurement that potentially predicts the presence or the risk of metastases.
Personalized Healthcare
SmartKidney Dx is designed with the intention of identifying patients who are candidates for additional therapy, due to undiagnosed micro-metastases by the current standard of care.
This test aims to help accelerate the course of treatment by reducing risk of disease progression through early intervention.
Partnered and collaborated on the development of SmartKidney Dx with Mayo Clinic and licensed with Mayo Ventures.